Thus, the formulation showed its potential to be used in the treatment of NSCLC due to its greater antitumor efficacy, synergistic activity and low systemic toxicity as it was conjugated with EGF to achieve its active targeting. The gene discussed is EGF; the disease is non-small cell lung carcinoma.